Stealth BioTherapeutics Awarded Grant from The Michael J. Fox Foundation to Support Development of SBT-272 in Parkinson’s Disease Press Release / August 9, 2023June 3, 2024
Stealth BioTherapeutics CEO Reenie McCarthy Highlights Opportunities and Challenges in Ultra-Rare Disease Drug Development at World Orphan Drug Congress USA Event / June 14, 2023June 3, 2024
Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration Press Release / June 12, 2023June 3, 2024
Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories Press Release / May 30, 2023June 3, 2024
Stealth BioTherapeutics Presents at the 2023 JMP Securities Life Sciences Conference Event / May 15, 2023May 16, 2023
Stealth BioTherapeutics to Present Overview of Elamipretide Clinical Development Program in Barth Syndrome at the 2023 American College of Medical Genetics Meeting Press Release / March 9, 2023June 3, 2024
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Press Release / November 1, 2022June 3, 2024
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events Press Release / September 15, 2022June 3, 2024
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome Press Release / June 14, 2022June 3, 2024
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium Uncategorized / June 8, 2022June 3, 2024
